文献速递浆细胞疾病

4色与8色荧光抗体组合检测多发性骨髓瘤微小残留病的比较与分析

[Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

该研究建立含CD38/CD138设门的8色抗体组合及6组4色抗体组合,检测20名健康志愿者和73例完全缓解后多发性骨髓瘤患者标本。8色组合识别异常浆细胞和克隆性浆细胞阳性率均为82.19%,一致率89.04%,敏感度0.004%。结论认为CD38/CD138设门更准确,胞膜抗原和胞质轻链同时检测更优,4色组合中推荐M1-(45/19)和MC2-(CD138)。

要点

  • 8色组合识别异常浆细胞和克隆性浆细胞阳性率均为82.19%,一致率89.04%。
  • 4色组合中C组MRD阳性率最低为65.75%,低于8色组合的82.19%(P=0.024)。
  • 4色组合中MC2-(CD138)组敏感性、准确性和阴性预测值最高,其次为M1-(45/19)组。

核心结论

  • CD38/CD138设门更准确,反映克隆性的胞质轻链检测较胞膜抗原更敏感。
  • 胞膜抗原异常表达并不完全代表为克隆性浆细胞,建议胞膜抗原和胞质轻链同时检测。
  • 有条件者建议选用8色组合,4色组合中建议同时采用M1-(45/19)和MC2-(CD138)组合。

研究设计与样本

  • 建立一组以CD38/CD138设门、同时检测胞膜抗原CD45、CD19、CD56、CD117及胞质轻链cKappa、cLambda的8色抗体组合。
  • 建立6组4色抗体组合,其中4组以CD38/CD138设门分别分析CD45/CD19、CD56/CD117、CD19/CD56胞膜抗原(M1-3)和胞质轻链(C组)表达。
  • MC1-2组分别以CD38/SSC和CD138/SSC设门,同时检测CD19或CD45胞膜抗原和胞质轻链。
  • 采用以上组合对20名健康志愿者和73例完全缓解后多发性骨髓瘤患者标本进行检测并比较分析。

主要发现

  • 8色组合识别异常浆细胞和克隆性浆细胞的阳性率均为82.19%,一致率为89.04%(65/73)。
  • 克隆性浆细胞中位比例为0.105%,均显示明显的单克隆轻链,敏感度为0.004%。
  • CD38/SSC设门的浆细胞比例明显高于CD38/CD138(P<0.001)和CD138/SSC(P=0.001)设门。
  • 4色组合中C-(胞质)组MRD阳性率最低为65.75%,明显低于8色组合的82.19%(P=0.024)。
  • M2-(56/117)组检测的异常浆细胞比例最低为0.095%,与其他组相比差异有统计学意义(P=0.014)。

临床怎么用

  • 作者建议胞膜抗原和胞质轻链同时检测。
  • 作者建议有条件者选用8色组合。
  • 作者建议4色组合中同时采用M1-(45/19)和MC2-(CD138)组合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore and compare 4-color and 8-color fluorescence antibody panels for detecting minimal residual disease of multiple myeloma patients after therapy. Methods: One 8-color antibody panel was built including CD38 and CD138 for the identification of plasma cells (PCs) , membrane antigen CD45, CD19, CD56 and CD117, cytoplasmic Kappa (cκ) and Lambda (cλ) light chain antigen. Six tubes of 4-color panels were built, among them, membrane antigen CD45/CD19, CD56/CD117, CD19/CD56 and light chains were analyzed combined by CD38/CD138 for PCs gate in the tubes M1-3 and tube C-(κ/λ), respectively; CD19 or CD45 and cκ/cλ light chains were detected in the tube MC1-(C)D38 for CD38/SSC identified PCs gate and tube MC2-(CD138) for CD138/SSC identified PCs gate separately. Twenty normal volunteer bone marrows and seventy-three specimens from multiple myeloma patients after complete remission were measured and analyzed. Results: MRD positive samples were discriminated in 82.19% of the specimen evaluated through either abnormal plasma cells (aPCs) or clonal plasma cells (cPCs) by 8-color antibody panel. Among of them, consistency was 89.04%. The median percentage of cPCs was 0.105%. The lowest sensitivity of experiment was 0.004%. Percentage of PCs identified by CD38/ SSC gate was higher than that by CD38/CD138 (P<0.001) and CD138/SSC gate (P=0.001) apparently. The lowest MRD positive rate was found in tube C (65.75%) , which lower than 8-color panel obviously (P=0.024) . The percentages of aPCs measured by tube M2-(56/117) were significantly lower than other tubes (P=0.014) . MRD positive rate determined by cPCs was higher than that by aPCs both in the tube MC1-(C)D38 and tube MC2-(CD138), whose concordance rate were 68.49% and 79.45%, respectively. Compared with 8-color panel, tube MC2-(CD138) the best choice among six tubes of 4-color panels, which has the best sensitivity, accuracy and negative predicted value, higher positive predicted value and specificity. Tube M1-(45/19) was the second choice. Conclusions: CD38/CD138 are the best markers for gating PCs. Membrane antigen and cκ/cλ detected simultaneously is a better method for MM MRD detection and 8-color antibody panel is an ideal approach. Two tubes of 4-color antibody combination, M1-(45/19) and MC2-(CD138) are recommended in the 4-color panels. 目的: 探讨与比较4色和8色荧光抗体组合检测多发性骨髓瘤(MM)患者治疗后微小残留病(MRD)的灵敏度。 方法: 建立一组以CD38/CD138对浆细胞进行设门,同时检测胞膜抗原CD45、CD19、CD56、CD117及胞质轻链cKappa、cLambda的8色抗体组合;6组4色抗体组合中,4组以CD38/CD138设门,分别分析CD45/CD19、CD56/CD117、CD19/CD56胞膜抗原(M1-3)和胞质轻链(C组)表达;MC1-2组分别以CD38/SSC和CD138/SSC设门,同时检测CD19或CD45胞膜抗原和胞质轻链。采用以上组合对20名健康志愿者和73例完全缓解后MM患者标本进行检测并进行比较分析。 结果: 8色组合识别异常浆细胞(aPCs)和克隆性浆细胞(cPCs)的阳性率均为82.19%,一致率为89.04%(65/73);cPCs中位比例为0.105%,均显示明显的单克隆轻链;敏感度为0.004%。CD38/SSC设门的浆细胞比例明显高于CD38/CD138(P<0.001)和CD138/SSC(P=0.001)设门。4色组合中C-(胞质)组MRD阳性率最低,仅为65.75%,明显低于8色组合的82.19%(P=0.024);M2-(56/117)组检测的aPCs比例最低,为0.095%,与其他组相比差异有统计学意义(P=0.014);MC1-(CD38)和MC2-(CD138)组,以cPCs作为判断标准时MRD阳性率均高于以aPCs为判断标准(P<0.05),结果一致率分别为68.49%(50/73)和79.45%(58/73)。与8色组合相比,4色组合中MC2-(CD138)组敏感性、准确性和阴性预测值最高,阳性预测值和特异性也较高;其次是M1-(45/19)组。 结论: CD38/CD138设门更准确,反映克隆性的胞质轻链检测较胞膜抗原更敏感,胞膜抗原异常表达并不完全代表为cPCs,建议胞膜抗原和胞质轻链同时检测。有条件者建议选用8色组合,4色组合中建议同时采用M1-(45/19)和MC2-(CD138)组合。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang YZ, Lu J, Hao L, et al. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28468086. doi:10.3760/cma.j.issn.0253-2727.2017.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。